GleamWall
中文EN

CING Cingulate Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1862150 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-30.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-240.8%
ROA-151.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.2%
Debt / equity0.00x
Current ratio3.90x
Interest coverage-25.09x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$9.77M$9.45M
SG&A expense$10.16M$6.20M
Operating income-$19.94M-$15.64M
Interest expense$901,325$25,354
Pretax income-$22.45M-$16.56M
Net income-$22.45M-$16.56M
EBITDA-$19.40M-$14.99M
EPS (basic)-4.44-10.86
EPS (diluted)-4.44-10.86
Weighted avg. shares (diluted)5.06M1.52M
Banking
Net interest income-$1.36M$99,236
Balance sheet
Cash & equivalents$10.95M$12.21M
Current assets$12.01M$12.66M
PP&E, net$1.73M$2.10M
Total assets$15.07M$14.86M
Current liabilities$10.31M$4.97M
Total liabilities$12.56M$7.41M
Shareholders' equity$2.51M$7.46M
Shares outstanding7.25M3.40M
Cash flow statement
Operating cash flow-$17.25M-$18.45M
Capital expenditure$162,138$211,800
Free cash flow-$17.41M-$18.66M
Investing cash flow-$162,138-$211,800
Financing cash flow$16.15M$30.82M
Depreciation & amortization$540,894$653,090
Stock-based compensation$1.52M$995,484

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.